Hester Biosciences Share Price Today

Hester Biosciences approves ₹10.50 million investment in Slyce Agri World

Hester Biosciences approved up to ₹10.50 million investment in Slyce Agri World LLP. Stake represents 26% of fixed capital for group captive power generation. Investment structured as cash consideration in one or more tranches. Slyce Agri World LLP reported FY25 turnover of ₹22.40 million.

SEC Commissioner Peirce calls crypto self-custody a fundamental right

Hester Peirce criticized rules restricting crypto investments compared to gambling. Proposed $5 million simplified exemption and $75 million stricter option for capital raising. Advocated for tokenized stocks trading via automated market makers on blockchains. Described crypto self-custody as a fundamental American right requiring regulatory preservation.

Hester Biosciences closes trading window from October 1 for Q2FY27

Trading window closed from October 1, 2026. Closure applies to Q2FY27 and H1FY27 results. Window reopens 48 hours after results are public. Compliance with SEBI insider trading regulations.

Hester Biosciences shareholders approve promoter reclassification

Shareholders approved reclassifying two promoters as public shareholders. Resolution passed with 99.99% assent via remote e-voting. Mr. Ravin Gandhi and Ms. Bela Gandhi affected by the change. Promoter group polled 77.42% of shares with full support.

Hester Biosciences seeks shareholder approval to reclassify promoter group

Hester Biosciences Limited is conducting a postal ballot to reclassify Ravin Gandhi and Bela Gandhi from promoter to public shareholders, following no-objection letters from BSE and NSE. The duo holds a combined 9.45% stake and meets all SEBI criteria for reclassification, including non-control status and lack of board representation. Remote e-voting via CDSL runs from August 5 to September 3, 2026, with results due by September 4. The move ensures continued compliance with minimum public shareholding norms.

Hester Biosciences Poultry revenue surges 48% in Q1FY27; management cites deeper market penetration

Hester Biosciences posted a 459% YoY profit surge in Q1FY27, largely due to an ₹853.49M exceptional gain from debt restructuring with the Gates Foundation. Standalone revenue rose 14% to ₹726.60M, led by a 48% jump in Poultry Healthcare, while Animal Healthcare fell 50% due to tender delays. Consolidated debt stands at ₹103 crore.